» Articles » PMID: 36551965

The Association of CD8+ Cytotoxic T Cells and Granzyme B+ Lymphocytes with Immunosuppressive Factors, Tumor Stage and Prognosis in Cutaneous Melanoma

Overview
Journal Biomedicines
Date 2022 Dec 23
PMID 36551965
Authors
Affiliations
Soon will be listed here.
Abstract

The immunosuppressive tumor microenvironment (TME) consists of suppressive cells producing a variety of immunomodulatory proteins, such as programmed death ligand 1 (PD-L1) and indoleamine-2,3-dioxygenase (IDO). Although granzyme B (GrB) is known to convey the cytolytic activities of CD8+ cytotoxic lymphocytes, it is also expressed by other cells, such as regulatory T and B cells, for immunosuppressive purposes. The role of GrB+ lymphocytes in melanoma has not been examined extensively. In this study, benign, premalignant, and malignant melanocytic tumors were stained immunohistochemically for CD8 and GrB. PD-L1 was also stained from malignant samples that had accompanying clinicopathological data. The association of CD8+ and GrB+ lymphocytes with PD-L1 expression, tumor stage, prognosis, and previously analyzed immunosuppressive factors were evaluated. Our aim was to obtain a more comprehensive perception of the immunosuppressive TME in melanoma. The results show that both CD8+ and GrB+ lymphocytes were more abundant in pT4 compared to pT1 melanomas, and in lymph node metastases compared to primary melanomas. Surprisingly, a low GrB/CD8 ratio was associated with better recurrence-free survival in primary melanomas, which indicates that GrB+ lymphocytes might represent activated immunosuppressive lymphocytes rather than cytotoxic T cells. In the present study, CD8+ lymphocytes associated positively with both tumor and stromal immune cell PD-L1 and IDO expression. In addition, PD-L1+ tumor and stromal immune cells associated positively with IDO+ stromal immune and melanoma cells. The data suggest that IDO and PD-L1 seem to be key immunosuppressive factors in CD8+ lymphocyte-predominant tumors in CM.

Citing Articles

Revealing the role of regulatory b cells in cancer: development, function and treatment significance.

Ye R, Li S, Li Y, Shi K, Li L Cancer Immunol Immunother. 2025; 74(4):125.

PMID: 39998678 PMC: 11861783. DOI: 10.1007/s00262-025-03973-w.


Predominance of CD4+ T cells in metastatic cervical lymph nodes in papillary thyroid carcinoma.

Moma C, Barreto I, Assumpcao L, Zantut-Wittmann D Endocr Connect. 2024; 13(8).

PMID: 38913547 PMC: 11301539. DOI: 10.1530/EC-24-0135.


Anti-Inflammatory and Anticancer Effects of Anticoagulant Therapy in Patients with Malignancy.

Russo V, Falco L, Tessitore V, Mauriello A, Catapano D, Napolitano N Life (Basel). 2023; 13(9).

PMID: 37763292 PMC: 10532829. DOI: 10.3390/life13091888.

References
1.
Sebestyen T, Mohos A, Liszkay G, Somlai B, Gaudi I, Ladanyi A . Correlation with lymphocyte infiltration, but lack of prognostic significance of MECA-79-positive high endothelial venules in primary malignant melanoma. Melanoma Res. 2018; 28(4):304-310. DOI: 10.1097/CMR.0000000000000457. View

2.
Fu Q, Chen N, Ge C, Li R, Li Z, Zeng B . Prognostic value of tumor-infiltrating lymphocytes in melanoma: a systematic review and meta-analysis. Oncoimmunology. 2019; 8(7):1593806. PMC: 6527267. DOI: 10.1080/2162402X.2019.1593806. View

3.
Vycital O, Dubova M, Palek R, Hosek P, Branzovsky J, Treska V . The Impact of Immune Interaction on the Metastatic Infiltration of Colorectal Carcinoma to Lymph Nodes. Anticancer Res. 2018; 38(7):4159-4167. DOI: 10.21873/anticanres.12709. View

4.
van Houdt I, Sluijter B, van Leeuwen P, Moesbergen L, Hooijberg E, Meijer C . Absence of Granzyme B positive tumour-infiltrating lymphocytes in primary melanoma excisional biopsies is strongly associated with the presence of sentinel lymph node metastasis. Cell Oncol. 2009; 31(5):407-13. PMC: 4619113. DOI: 10.3233/CLO-2009-0485. View

5.
Erdag G, Schaefer J, Smolkin M, Deacon D, Shea S, Dengel L . Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res. 2012; 72(5):1070-80. PMC: 3306813. DOI: 10.1158/0008-5472.CAN-11-3218. View